Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments
04 janv. 2024 07h18 HE
|
Clearmind Medicine Inc.
The collaboration included filing six different US patent applications with the United States Patent and Trademark Office to protect novel combinations of psychedelics with SciSparc's PEA Tel Aviv,...
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
16 juin 2023 09h05 HE
|
Clearmind Medicine Inc.
The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary...
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
07 juin 2023 08h05 HE
|
Jeffs' Brands Ltd
Tel Aviv, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company” or “Jeffs' Brands”) (Nasdaq: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, today...
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
21 avr. 2023 08h30 HE
|
Clearmind Medicine Inc.
The application is for a novel psychedelic-based combination, of Clearmind's MEAI and SciSparc's Cannamide™ Tel Aviv, Israel / Vancouver, Canada, April 21, 2023 (GLOBE NEWSWIRE) --...
Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million
23 févr. 2023 08h45 HE
|
Jeffs' Brands Ltd
The food supplements and cosmetics brand is profitable with millions of dollars in gross annual sales Tel Aviv, Israel, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd (the “Company” or...
Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds
22 févr. 2023 08h00 HE
|
Clearmind Medicine Inc.
The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc's PEA Tel Aviv, Israel /...
SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
29 nov. 2022 08h00 HE
|
SciSparc Ltd
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
SciSparc Gains Competitive Edge with Additional U.S. Patent Granted
08 nov. 2022 07h00 HE
|
SciSparc Ltd
This patent extends protection, adding to six other U.S. patents already granted TEL AVIV, Israel, Nov. 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage...
SciSparc Completes the Acquisition of Wellution™, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million
30 sept. 2022 07h00 HE
|
SciSparc Ltd
Wellution™ offers dozens of products including natural supplements, creams, gels and hemp-based products on Amazon.com Marketplace TEL AVIV, Israel, Sept. 30, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders
12 août 2022 08h00 HE
|
SciSparc Ltd
Patent extends protection for SciSparc’s novel compounds and methods already granted in the U.S., Australia and Japan TEL AVIV, Israel, Aug. 12, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:...